• Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

    13 days ago - By San Diego Biotechnology

    LA JOLLA, Calif., Oct. 15, 2020 /PRNewswire/ - Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today announced......
    Read more ...